Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis

Author(s):
Quistrebert, J.; Hassler, S.; Bachelet, D.; Mbogning, C.; Musters, A.; Tak, P.P.; Wijbrandts, C.A.; Herenius, M.; Bergstra, S.A. (0000-0002-7136-5248); Akdemir, G.; Johannesson, M.; Combe, B.; Fautrel, B.; Chollet-Martin, S.; Gleizes, A.; Donnellan, N.; Deisenhammer, F.; Davidson, J.; Hincelin-Mery, A.; Donnes, P.; Fogdell-Hahn, A.; Vries, N. de; Huizinga, T.; Abugessaisa, I.; Saevarsdottir, S.; Hacein-Bey-Abina, S.; Pallardy, M.; Broet, P.; Mariette, X.; ABIRISK Consortium
Published
2019
Publication type
Article / Letter to editor
Rheumatoid arthritisAnti-drug antibodiesAnti-TNF treatmentIncidenceRisk factors
Date issued
2019-06-30
Language
English
Is part of
Seminars in Arthritis and Rheumatism (2019), Vol. 48, no. 6, p. 967-975
hdl
1887/119992
doi
10.1016/j.semarthrit.2018.10.006